Gar-Yang Chau
- Hepatology top 0.2%
- Epidemiology top 2%
- Oncology top 5%
- Molecular Biology
- Cancer Research top 5%
- Co-authors
- Jaw‐Ching WuChien‐Wei SuWon Young TakJordi BruixJosep M. LlovetJiamei YangGerold MeinhardtShou‐Dong Lee
- Topics
- Hepatocellular Carcinoma Treatment and Prognosis (26 papers)Liver Disease Diagnosis and Treatment (12 papers)Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers)
- Journals
- PLoS ONEHepatologyAnnals of Surgery
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Gar-Yang Chau
37 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 87
- Hepatology 2.0k
- Epidemiology 1.1k
- Oncology 634
- Molecular Biology 589
- Cancer Research 575
Countries citing papers authored by Gar-Yang Chau
This map shows the geographic impact of Gar-Yang Chau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gar-Yang Chau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gar-Yang Chau more than expected).
Fields of papers citing papers by Gar-Yang Chau
This network shows the impact of papers produced by Gar-Yang Chau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gar-Yang Chau. The network helps show where Gar-Yang Chau may publish in the future.
Co-authorship network of co-authors of Gar-Yang Chau
This figure shows the co-authorship network connecting the top 25 collaborators of Gar-Yang Chau. A scholar is included among the top collaborators of Gar-Yang Chau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gar-Yang Chau. Gar-Yang Chau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 13 | |
| 3 | 56 | |
| 4 | Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trialbreakdown → | 479 |
| 5 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialbreakdown → | 771 |
| 6 | 15 | |
| 7 | 69 | |
| 8 | 22 | |
| 9 | 27 | |
| 10 | 28 | |
| 11 | 110 | |
| 12 | 16 | |
| 13 | 48 | |
| 14 | 38 | |
| 15 | 29 | |
| 16 | 9 | |
| 17 | 191 | |
| 18 | 19 | |
| 19 | 19 | |
| 20 | 174 |
About Gar-Yang Chau
Gar-Yang Chau is a scholar working on Hepatology, Cancer Research and Epidemiology, having authored 37 papers that have together received 2.9k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (26 papers), Liver Disease Diagnosis and Treatment (12 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers). The work is most often cited by research in Hepatology (2.0k citations), Cancer Research (575 citations) and Epidemiology (1.1k citations). Gar-Yang Chau has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Jaw‐Ching Wu, Chien‐Wei Su, Won Young Tak, Jordi Bruix, Josep M. Llovet, Jiamei Yang, Gerold Meinhardt, Shou‐Dong Lee, Teh‐Ia Huo and Jianqiang Cai. Their work appears in journals such as PLoS ONE, Hepatology and Annals of Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.